SPOTLIGHT -
Challenges With a Precision Medicine-Based Approach in Oncology
Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.
Read More
Holli Dilks on Molecular Profiling
Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
